Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies
US11174323B2 · kind B2 · utility
2Cited by
23References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2019 |
| Grant date | Nov 16, 2021 |
| Priority date | — |
| Expiry date | Dec 29, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.